Home » Newsletters » BioWorld

BioWorld

Dec. 15, 2003

View Archived Issues

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld Today) Read More

Xanthus Series B Gets $30.8M To Advance Phase II Program

New-Found Proteins Cause Iron Overload Ailment In Body, But Presage Hemochromatosis Cure

VasGene Uses ASH Platform To Tout Anti-VEGF Cancer Product

Correction

Other News To Note